Impact of the MeNZB™ vaccine on gonorrhoea Event as iCalendar

(School of Social Sciences)

29 April 2016

3 - 4pm

Venue: Room 104, Fale Pasifika Complex (273-104)

Contact info: Dr Barry Milne

Contact email:

Website: COMPASS

Dr Janine Paynter, General Practice and Primary Healthcare

Observational data from Cuba and Norway suggest a limited effect of a protein-based meningococcal B vaccine against gonorrhoea. Neisseria gonorrhoeae the bacteria that causes gonorrhoea and Neisseria meningitidis, a bacteria which causes meningitis are related. Based on DNA- DNA hybridisation there is between 80–90% homology of primary sequences between N.gonorrhoeae and N. meningitidis. New Zealand’s immunisation against meningococcal B from 2004-2008 plus comprehensive documentation of immunisation with MeNZB™ for safety purposes, New Zealand’s national health index, the Integrated Data infrastructure and good sexual health clinic records have enabled us to conduct both a retrospective case-control and cohort study which tests for an effect of the MeNZB™ vaccine on gonorrhoea in New Zealand. I’ll be reporting on the interim results of the case-control study and describing the cohort study. The project is led by Dr Helen Petousis-Harris, funded by Novartis Vaccines & Diagnostics AG (a member of the GlaxoSmithKline group) and sponsored by Auckland UniServices Ltd.

Janine Paynter studied science at the University of Adelaide. She has had an unconventional career path with research experience on caddis flies, nematodes, powdery mildew, phytoplasmas in sugar cane, weedy legume ecology (PhD research) and seems to have settled in public health/epidemiology with 8 years’ experience in tobacco control and two years in vaccine epidemiology.

Join the Faculty of Arts Public Lecture Mailing List